Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enwave Corp V.ENW

Alternate Symbol(s):  NWVCF

EnWave Corporation is an applied dehydration technology company. The Company’s principal business is the licensing of its intellectual property through royalty-bearing agreements and the design, construction, marketing, and sales of vacuum-microwave dehydration machinery for the food, cannabis and biomaterial industries. It has entered into 54 royalty-bearing commercial licenses with and sold REV equipment to a diverse portfolio of companies operating in over 23 different countries on five continents. It also operates REVworx, a toll processing facility located in Delta, British Columbia that offers vacuum-microwave contract manufacturing services. The REVworx facility houses both a batch 10 kilowatt (kW) and 60 kW continuous vacuum-microwave line to accelerate the commercialization of products made with the Company’s patented technology. The Company has two primary commercial scale technologies, nutraREV, a drum-based system, and quantaREV, a tray-based system.


TSXV:ENW - Post by User

Bullboard Posts
Post by risetothetopon Apr 26, 2018 4:42pm
123 Views
Post# 27946838

Sutro Biopharma initiates first clinic trial

Sutro Biopharma initiates first clinic trial

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs:

https://www.prnewswire.com/news-releases/sutro-initiates-first-clinical-trial-of-cd74-targeting-adc-for-lymphoma--multiple-myeloma-treatment-the-first-of-a-new-generation-of-precisely-engineered-adcs-300636962.html


I'm a little surprised we haven't received much of an update on Sutro Biopharma.  Last year I believe John Budreski anticipated starting commercial production with Sutro by the end of 2017.  In February, ENW stated that they were conducting factory acceptance trials.  If they are successful, this would open the door to a number of other pharma projects IMO.  


 

Bullboard Posts